FAP-targeted gold nanocluster-mediated radioligand therapy in combination with TGF-βRI inhibition for tumor therapy.

Authors

Huizhen Yang, Liu Liu, Guoping Jia, He Gao, Wangxi Hai, Qinghe Wu, Jia Xu, Yifei Jiang, Chunfu Zhang

Published in

Biomaterials. Volume 338. Issue Pt A. Pages 124605. Sep 04, 2026. Epub Sep 04, 2026.

Abstract

Targeted radioligand therapy (TRT) is an emerging treatment modality that selectively delivers radioisotopes to tumors while sparing healthy tissues. However, optimizing TRT radiopharmaceuticals to concurrently achieve sustained tumor retention and rapid systemic clearance remains a fundamental challenge. Gold nanoclusters with favorable pharmacokinetic properties and tunable blood half-life are advantageous in addressing this issue. Here, we develop a renally clearable GN-based TRT agent (GN_FAPI) that efficiently chelates diagnostic ⁶⁸Ga or therapeutic ¹⁷⁷Lu isotopes, conferring precise targeting of fibroblast activation protein (FAP)-enriched and cancer-associated fibroblast (CAF)-dominated tumor stroma for integrated tumor theranostics. PET imaging demonstrates high tumor-specific uptake and renal clearance of ⁶⁸Ga-GN_FAPI in multiple models, with minimal retention in the liver and spleen. For treatment, we propose the Radio-Hook based Crosstalk Cut (RHCC) strategy, synergizing ¹⁷⁷Lu-GN_FAPI with a TGF-βRI inhibitor. This strategy utilizes β-radiation from ¹⁷⁷Lu-GN_FAPI like a powerful "hook" to disrupt the stroma and tumor cells, while the inhibitor blocks tumor-stromal crosstalk, thus abrogating the TGF-β-CAF-tumor feedback loop to suppress residual CAF reactivation, inhibit metastasis, and enhance antitumor immunity. Moreover, species-specific transcriptomics in patient-derived xenograft (PDX) models further elucidates the underlying mechanisms. Validation across various tumor models, achieving complete responses in some instances, supports its clinical translational promise.

PMID:
42702119
Bibliographic data and abstract were imported from PubMed on 07 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.